In re Cassava Sciences, Inc. Securities Litigation; Carlos Pérez-Cotapos Ugarte, et al. v. Cassava Sciences, Inc., et al.

District Court, W.D. Texas·Decided June 29, 2026·No. 1:24-cv-01525·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

IN RE CASSAVA SCIENCES, INC. Master File No. 1:21-cv-00751-DAE SECURITIES LITIGATION CONSOLIDATED CLASS ACTION

CARLOS PÉREZ-COTAPOS UGARTE, Case No. 1:24-cv-01525-DAE et al., Plaintiffs v. CLASS ACTION

CASSAVA SCIENCES, INC., et al., Defendants

ORDER

Now before the Court are: 1. Defendants Cassava Sciences, Inc., Remi Barbier, Lindsay Burns, and Eric J. Schoen’s Opposed Motion to Consolidate, filed September 18, 2025 (Dkt. 338 in 1:21-cv- 00751-DAE; Dkt. 53 in 1:24-cv-01525-DAE); 2. Defendants’ Motion to Strike Plaintiffs’ Opposition to Defendants’ Motion to Consolidate, filed October 20, 2025 (Dkt. 346 [sealed] in 1:21-cv-00751-DAE); 3. Plaintiffs’ Motion for Leave to File Notice of Supplemental Authority in Further Support of Their Opposition to Defendants’ Motion to Strike and Opposition to Defendants’ Motion to Consolidate, filed December 30, 2025 (Dkts. 360 [redacted] and 368 [sealed] in 1:21-cv-00751-DAE); 4. Plaintiffs’ Opposed Motion for Leave to Lodge Mediator’s May 3, 2026 Ruling for In Camera Review Pursuant to Local Rule CV-88(f)(3), filed May 14, 2026 (Dkt. 375 [sealed] in 1:21-cv-00751-DAE); and the associated response and reply briefs.1 On June 24, 2026, the Court held a hearing on the motions at which the parties appeared through counsel.

1 The Honorable David A. Ezra referred the motions to this Magistrate Judge for disposition, pursuant to 28 U.S.C. § 636(b)(1)(A), Federal Rule of Civil Procedure 72, and Rule 1(c) of Appendix C of the Local Court Rules of the United States District Court for the Western District of Texas. Dkts. 356 and 365 and Text Orders entered February 20 and May 27, 2026 in 1:21-cv-00751-DAE; Dkt. 71 in 1:24-cv-01525- DAE. I. Background Plaintiffs bring these securities class actions against biotechnology company Cassava Sciences, Inc. and former executives. Cassava developed an experimental drug, simufilam, as a treatment for Alzheimer’s disease. Amended Complaint, Dkt. 49 ¶ 2 in 1:24-cv-1525-DAE. Plaintiffs allege that Cassava repeatedly made false and misleading public statements about the

efficacy of simufilam and the results of its clinical trials, which (1) deceived the investing public, (2) artificially inflated the market price of Cassava securities, and (3) caused Plaintiffs and others to acquire Cassava’s securities at artificially inflated prices. Id. ¶ 266. Plaintiffs allege that Defendants’ actions violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Securities and Exchange Commission (“SEC”) Rule 10b-5. On August 27, 2021, Plaintiff Pierre Brazeau filed the first securities class action in this Court against Cassava, founder Remi Barbier, Eric J. Schoen, James W. Kupiec, Nadav Friedmann, and Michael Marsman. Brazeau v. Cassava Sciences, Inc., et al., No. 1:21-cv-00751-DAE (W.D. Tex). Several other class actions were filed and the Court consolidated them with Brazeau (“Consolidated Action”), ordering: “Any other actions now pending or hereafter filed in this

District that arise out of the same facts and claims as alleged in the above-listed related actions shall be consolidated into the Consolidated Action for all purposes once the Court is informed of them.” Id. at Dkt. 58 ¶ 5. The Court appointed Mohammad Bozorgi as Lead Plaintiff and Robbins Geller Rudman & Dowd LLP as Lead Counsel. Id. at Dkt. 59. On August 12, 2025, the Court certified a class in the Consolidated Action of all purchasers or acquirers of Cassava securities between September 14, 2020 and October 12, 2023. Id. at Dkt. 332.2

2 Appeal of the class certification order is pending before the Fifth Circuit in Case No. 25-50855. The SEC filed securities fraud charges on September 26, 2024, alleging that Cassava, Barbier, and Burns made misleading statements about the results of clinical trials for simufilam against. SEC v. Cassava Scis., Inc., No. 1:24-cv-01150-DAE (W.D. Tex. Sept. 26, 2024). The parties settled and the Court entered final On December 12, 2024, Stephen Crocker filed another class action against Cassava, Kupiec, and director Richard Jon Barry. Ugarte v. Cassava Sciences, Inc., et al., No. 1:24-cv-01525-DAE (“Ugarte”). Crocker sought to certify a class of investors who acquired Cassava securities between February 7, 2024 and November 24, 2024. Id. at Dkt. 1 ¶ 1. Carlos Pérez-Cotapos Ugarte, Maria Isabel Ureta Bazán, and Inversiones Ane Miren Limitada were appointed Lead Plaintiffs, and

Pomerantz LLP and Bronstein, Gewirtz & Grossman, LLC as Co-Lead Counsel. Id. at Dkt. 42. Lead counsel in Ugarte are different from those in the Consolidated Action. Two weeks after the Court certified the class in the Consolidated Action, the Ugarte Plaintiffs amended their complaint to add Barbier, Schoen, and Dr. Lindsay Burns as defendants and change the proposed class to all who acquired Cassava securities between October 13, 2023 and March 25, 2025 – a period beginning the day after the end of the class period certified in the Consolidated Action. Id. at Dkt. 49 ¶ 258. Defendants filed motions to dismiss the Amended Complaint, which are pending. Id. at Dkts. 69-70. In their motions to consolidate, Defendants argue that the cases should be consolidated under

Rule 42(a) because the claims in Ugarte arise out of the same facts and claims as those alleged in the Consolidated Action. Plaintiffs respond that consolidation would be improper because the parties settled the Consolidated Action in August 2025. Plaintiffs contend that Defendants failed to secure a release of the Ugarte claims during mediation and now seek consolidation “hoping to achieve what they could not bargain for: a global release that extinguishes the Ugarte claims without paying a dime of additional consideration.” Dkt. 345 at 3 in 1:21-cv-00751-DAE [sealed]. They characterize Defendants’ motion to consolidate as “a transparent, opportunistic attempt to escape the deal they knowingly and willingly made.” Id. at 2.

Free access — add to your briefcase to read the full text and ask questions with AI

In re Cassava Sciences, Inc. Securities Litigation; Carlos Pérez-Cotapos Ugarte, et al. v. Cassava Sciences, Inc., et al., (W.D. Tex. 2026).

In re Cassava Sciences, Inc. Securities Litigation; Carlos Pérez-Cotapos Ugarte, et al. v. Cassava Sciences, Inc., et al. (In re Cassava Sciences, Inc. Securities Litigation; Carlos Pérez-Cotapos Ugarte, et al. v. Cassava Sciences, Inc., et al.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Zermeno v. McDonnell Douglas Corp.
246 F. Supp. 2d 646 (S.D. Texas, 2003)
Hall v. Hall
584 U.S. 59 (Supreme Court, 2018)
Parker v. Hyperdynamics Corp.
126 F. Supp. 3d 830 (S.D. Texas, 2015)
Ulibarri v. Novartis Pharmaceuticals Corp.
303 F.R.D. 402 (D. New Mexico, 2014)
Mills v. Beech Aircraft Corp.
886 F.2d 758 (Fifth Circuit, 1989)
Frazier v. Garrison I.S.D.
980 F.2d 1514 (Fifth Circuit, 1993)